Clinical Trial Update: Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ASC22 in combination with antiretroviral therapy for HIV infection has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• ASC22 (anti-PD-L1 monoclonal antibody)

Snippet

Sponsor: Ascletis Pharmaceuticals Co., Ltd. | Conditions: HIV-1-infection, HIV Infections | Phase 2 | Status: COMPLETED